New Two-Drug attack on Tough-to-Treat skin cancer
NCT ID NCT03131908
Summary
This study is testing whether adding an experimental pill called GSK2636771 to an approved immunotherapy drug (pembrolizumab) can help control advanced melanoma that has not responded to prior treatment and has a specific genetic feature called PTEN loss. The main goals are to find a safe dose for the combination and see if it shrinks tumors. The study will include up to 41 adults with this specific type of advanced melanoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.